Literature DB >> 9564462

Hyperparasitemia and blood exchange transfusion for treatment of children with falciparum malaria.

B Mordmüller1, P G Kremsner.   

Abstract

A substantial number of reports of cases and small investigations support blood exchange transfusion as a therapy for hyperparasitemia in cases of Plasmodium falciparum malaria, although a prospective and randomized study has never been undertaken. We report on 113 prospectively enrolled children in Lambaréné, Gabon, who had more than 10% parasitized erythrocytes and were treated with chemotherapy alone. All 86 patients with hyperparasitemia as the sole complication recovered uneventfully. Among the 27 patients who had additional complications, parasitemia levels as high as 81% responded well to chemotherapy alone. Two patients with cerebral malaria, who also had other complications and hence a poor prognosis, died. Hyperparasitemia itself might be important for the development of a fatal event in malaria, but a recommendation to perform a dangerous, expensive, and labor-intensive procedure such as blood exchange transfusion for its treatment should be based on substantial clinical research, especially in areas where malaria is a major health problem.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564462     DOI: 10.1086/513926

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

1.  Tropical medicine at the University of Tübingen.

Authors:  Peter Gottfried Kremsner
Journal:  Wien Klin Wochenschr       Date:  2010-03       Impact factor: 1.704

Review 2.  Current evidence and future of automated erythrocyte exchange in the treatment of severe malaria.

Authors:  Lorenz Auer-Hackenberg; Stefan Winkler; Wolfgang Graninger; Nina Worel; Michael Ramharter
Journal:  Wien Klin Wochenschr       Date:  2012-10-13       Impact factor: 1.704

Review 3.  ICU management of severe malaria.

Authors:  D Gupta; K Chugh; A Sachdev; A Soni
Journal:  Indian J Pediatr       Date:  2001-11       Impact factor: 1.967

4.  Need for optimized dosages in the design of comparative clinical trials of anti-malarial drugs.

Authors:  Sanjeev Krishna; Peter G Kremsner
Journal:  Malar J       Date:  2022-06-20       Impact factor: 3.469

Review 5.  Management of severe malaria.

Authors:  Tanu Singhal
Journal:  Indian J Pediatr       Date:  2004-01       Impact factor: 1.967

6.  Hemolysis is associated with low reticulocyte production index and predicts blood transfusion in severe malarial anemia.

Authors:  Rolf Fendel; Christian Brandts; Annika Rudat; Andrea Kreidenweiss; Claudia Steur; Iris Appelmann; Bettina Ruehe; Paul Schröder; Wolfgang E Berdel; Peter G Kremsner; Benjamin Mordmüller
Journal:  PLoS One       Date:  2010-04-06       Impact factor: 3.240

7.  Cerebral Malaria.

Authors:  Gretchen L. Birbeck
Journal:  Curr Treat Options Neurol       Date:  2004-03       Impact factor: 3.598

8.  Inter-observer agreement according to malaria parasite density.

Authors:  Mounkaila Abdou Billo; Mahamadou Diakité; Amagana Dolo; Mouctar Diallo; Belco Poudiougou; Sory Ibrahima Diawara; Eric S Johnson; Janet C Rice; Donald J Krogstad; Ogobara K Doumbo
Journal:  Malar J       Date:  2013-09-22       Impact factor: 2.979

9.  Automated red blood cell exchange as an adjunctive treatment for severe Plasmodium falciparum malaria at the Vienna General Hospital in Austria: a retrospective cohort study.

Authors:  Lorenz Auer-Hackenberg; Thomas Staudinger; Andja Bojic; Gottfried Locker; Gerda C Leitner; Wolfgang Graninger; Stefan Winkler; Michael Ramharter; Nina Worel
Journal:  Malar J       Date:  2012-05-07       Impact factor: 2.979

10.  Manual blood exchange transfusion does not significantly contribute to parasite clearance in artesunate-treated individuals with imported severe Plasmodium falciparum malaria.

Authors:  Annemarie R Kreeftmeijer-Vegter; Mariana de Mendonça Melo; Peter J de Vries; Rob Koelewijn; Jaap J van Hellemond; Perry J J van Genderen
Journal:  Malar J       Date:  2013-03-27       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.